In this study, we proposed that blocking ASNS phosphorylation could enhance its ubiquitination and degradation, suggesting that the S349 residue of ASNS may serve as an effective therapeutic target for patients with GC exhibiting elevated NEK8 expression. The gene discussed is NEK8; the disease is gastric cancer.